Confirmation of the fairly low chance to achieve disease remission with medical treatment is a clinically relevant conclusion that will adjust the expectations of patients and doctors, particularly because the current Endocrine Society guideline states that the risk of recurrence after withdrawal ranges from 26% to 69% depending on prolactin levels at diagnosis and tumor size (7). This evidence concerns the gene PRL and neoplasm.